Lorlatinib

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.[1] Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 7.1 Clinical studies 7.2 Approval... [wikipedia]